When David Ricks became CEO of Eli Lilly, he faced the usual pressures of making the right, albeit risky, bets on the next big pharmaceutical breakthrough. But he also faced a unique challenge ...

David Ricks, the CEO of Mounjaro and Zepbound maker Eli Lilly, explained why these medications are so expensive on the "In Good Company with Nicolai Tangen" podcast this week. 1.

David Ricks and Dr. Fatima Cody Stanford talk through the groundbreaking role of GLP-1 medications in transforming the treatment of obesity, and how they might reshape the future of health care ...

At the J.P. Morgan Healthcare Conference, Lilly CEO David Ricks explained why the company revised downward its projections for fourth quarter 2024 revenue. By Frank Vinluan on January 15, 2025 1:01 am ...

Eli Lilly forecasts $45 billion in 2024 revenue, a 32% growth but $400 million below Q3 guidance. Mounjaro and Zepbound expected to contribute $3.5 billion and $1.9 billion, respectively, to 2024 ...

It was revealed in a recent SEC filing that David Ricks, Board Member at Adobe (NASDAQ:ADBE) made a noteworthy insider purchase on January 31,. What Happened: Ricks's recent move, as outlined in a ...

Eli Lilly (LLY) CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the most valuable pharmaceutical company in the world.

Ricks on Friday said the company aims to bring its weight-loss pill to market in 2026. Eli Lilly shares rallied on the news, up 14% to $839.96. The stock is up around 8% year to date.

CEO David Ricks can see the companies setting up tents at basecamp behind Eli Lilly in an attempt to get a foothold of the obesity market. But Lilly's already been to the summit and is coming back ...

On the C-SPAN Networks: David A. Ricks is a President and CEO for the Eli Lilly and Company with four videos in the C-SPAN Video Library; the first appearance was a 2017 Remarks. The year with the ...